Anzeige
Meldung des Tages: Gold im Fokus: Warum diese milliardenschwere Goldaktie vom aktuellen Goldumfeld profitieren könnte

WuXi Biologics Aktie News

Aktie
WKN:  A2PQ3Q ISIN:  US98260N1081 US-Symbol:  WXXWY Branche:  Biotechnologie Land:  China
9,35 $
+0,00 $
0,00%
7,9367 € 21:56:14 Uhr
Depot/Watchlist
Marktkapitalisierung *
14,59 Mrd. €
Streubesitz
100,00%
KGV
-
Faktor
0.5
Originalaktie
KYG970081173

WuXi Biologics News

25.09.25 - PR Newswire
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability PR Newswire
23.09.25 - PR Newswire
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year PR Newswire
17.09.25 - PR Newswire
Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)
Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK) PR Newswire
11.09.25 - PR Newswire
WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards
WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards PR Newswire
09.09.25 - PR Newswire
WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry
WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry PR Newswire
28.08.25 - PR Newswire
WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi
WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi PR Newswire
19.08.25 - PR Newswire
WuXi Biologics Reports Solid 2025 Interim Results
WuXi Biologics Reports Solid 2025 Interim Results PR Newswire
18.08.25 - PR Newswire
WuXi Biologics Ireland Facility Receives EMA Approval for Commercial Manufacturing of Innovative Biologic
WuXi Biologics Ireland Facility Receives EMA Approval for Commercial Manufacturing of Innovative Biologic PR Newswire
12.08.25 - PR Newswire
WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-​Scale PR Newswire
12.08.25 - PR Newswire
WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-​Scale PR Newswire
11.08.25 - PR Newswire
WuXi Biologics bringt stabile HEK293-Zelllinienplattform WuXia293 Stable auf den Markt, um schwer zu exprimierende Moleküle zu entwickeln und herzustellen
WuXi Biologics bringt stabile HEK293-Zelllinienplattform WuXia293 Stable auf den Markt, um schwer zu exprimierende Moleküle zu entwickeln und herzustellen PR Newswire
11.08.25 - PR Newswire
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-​to-Express Molecules PR Newswire
11.08.25 - PR Newswire
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-​to-Express Molecules PR Newswire
06.08.25 - PR Newswire
WuXi Biologics Named to A List for CDP Supplier Engagement Assessment
WuXi Biologics Named to A List for CDP Supplier Engagement Assessment PR Newswire
29.07.25 - PR Newswire
WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication
WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication PR Newswire
22.07.25 - PR Newswire
WuXi Biologics Secures FDA PLI Approval for Five Facilities, First for Commercial PFS Line
WuXi Biologics Secures FDA PLI Approval for Five Facilities, First for Commercial PFS Line PR Newswire
16.07.25 - PR Newswire
WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics
WuXi Biologics Granted Highest Negligible-​Risk ESG Rating from Morningstar Sustainalytics PR Newswire
30.06.25 - PR Newswire
WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL
WuXi Biologics Launches Next-​Generation Platform WuXiHigh™2.0 for High-​Concentration Biologics with Protein Concentration Reaching 230 mg/mL PR Newswire
17.06.25 - PR Newswire
WuXi Biologics Ireland Receives 2025 Operational Excellence in Life Sciences Award
WuXi Biologics Ireland Receives 2025 Operational Excellence in Life Sciences Award PR Newswire
09.06.25 - PR Newswire
WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu
WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +8,85%
Technical Trading: Pfund Short im Februar
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »